Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chris Fegan

Showing results (1-10 of 58) with videos related to

Pageof 6
Sort By:
Blood|February 5, 2011
CLL: a supplementary question?Chris Pepper, Chris Fegan
Advances in Experimental Medicine and Biology|September 10, 2013
Apoptosis deregulation in CLLChris Fegan, Chris Pepper
British Journal of Haematology|March 13, 2019
Is venetoclax a new wonder drug in CLL?Chris Fegan, Chris Pepper
The Lancet. Oncology|February 2, 2015
Understanding cancer cell survival is key to patient survivalChris Fegan, Chris Pepper
Expert Review of Hematology|October 14, 2014
Telomere analysis to predict chronic lymphocytic leukemia outcome: a STELA test to change clinical practice?Chris Pepper, Duncan Baird, Chris Fegan
Future Oncology (London, England)|October 2, 2009
NF-kappaB as a prognostic marker and therapeutic target in chronic lymphocytic leukemiaChris Pepper, Saman Hewamana, Paul Brennan, et al.
Leukemia & Lymphoma|April 12, 2003
Flavopiridol induces apoptosis in B-cell chronic lymphocytic leukaemia cells through a p38 and ERK MAP kinase-dependent mechanismChris Pepper, Alun Thomas, Chris Fegan, et al.
Oncotarget|May 24, 2012
The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-κB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cellsElisabeth Walsby, Lawrence Pearce, Alan K Burnett, et al.
Blood|November 26, 2002
The vitamin D3 analog EB1089 induces apoptosis via a p53-independent mechanism involving p38 MAP kinase activation and suppression of ERK activity in B-cell chronic lymphocytic leukemia cells in vitroChris Pepper, Alun Thomas, Terry Hoy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 23, 2011
Expansion of a CD8(+)PD-1(+) replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progressionClaudia Nunes, Ryan Wong, Malcolm Mason, et al.
Pageof 6

Showing results (1-10 of 58) with videos related to

Sort By:
Pageof 6
Blood|February 5, 2011
CLL: a supplementary question?Chris Pepper, Chris Fegan
Advances in Experimental Medicine and Biology|September 10, 2013
Apoptosis deregulation in CLLChris Fegan, Chris Pepper
British Journal of Haematology|March 13, 2019
Is venetoclax a new wonder drug in CLL?Chris Fegan, Chris Pepper
The Lancet. Oncology|February 2, 2015
Understanding cancer cell survival is key to patient survivalChris Fegan, Chris Pepper
Expert Review of Hematology|October 14, 2014
Telomere analysis to predict chronic lymphocytic leukemia outcome: a STELA test to change clinical practice?Chris Pepper, Duncan Baird, Chris Fegan
Future Oncology (London, England)|October 2, 2009
NF-kappaB as a prognostic marker and therapeutic target in chronic lymphocytic leukemiaChris Pepper, Saman Hewamana, Paul Brennan, et al.
Leukemia & Lymphoma|April 12, 2003
Flavopiridol induces apoptosis in B-cell chronic lymphocytic leukaemia cells through a p38 and ERK MAP kinase-dependent mechanismChris Pepper, Alun Thomas, Chris Fegan, et al.
Oncotarget|May 24, 2012
The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-κB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cellsElisabeth Walsby, Lawrence Pearce, Alan K Burnett, et al.
Blood|November 26, 2002
The vitamin D3 analog EB1089 induces apoptosis via a p53-independent mechanism involving p38 MAP kinase activation and suppression of ERK activity in B-cell chronic lymphocytic leukemia cells in vitroChris Pepper, Alun Thomas, Terry Hoy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 23, 2011
Expansion of a CD8(+)PD-1(+) replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progressionClaudia Nunes, Ryan Wong, Malcolm Mason, et al.
Pageof 6